CRBU Caribou Biosciences, Inc.

Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.

$17.06  -0.95 (-5.28%)
As of 12/03/2021 15:59:57 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  11/16/2012
Outstanding shares:  60,192,061
Average volume:  373,223
Market cap:   $1,084,059,019
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    142038108
ISIN:        US1420381089
Sedol:      BNYJR68
Valuation   (See tab for details)
PE ratio:   -21.21
PB ratio:   2.53
PS ratio:   135.12
Return on equity:   -15.61%
Net income %:   -787.07%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy